KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non-Current Assets (2020 - 2025)

Historic Non-Current Assets for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $685.4 million.

  • Recursion Pharmaceuticals' Non-Current Assets rose 17164.0% to $685.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 20526.0%. This contributed to the annual value of $734.3 million for FY2024, which is 24065.79% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Non-Current Assets stood at $685.4 million, which was up 17164.0% from $715.2 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year Non-Current Assets high stood at $734.3 million for Q4 2024, and its period low was $50.1 million during Q1 2021.
  • Its 5-year average for Non-Current Assets is $269.5 million, with a median of $214.2 million in 2024.
  • Examining YoY changes over the last 5 years, Recursion Pharmaceuticals' Non-Current Assets showed a top increase of 24065.79% in 2024 and a maximum decrease of 755.56% in 2024.
  • Recursion Pharmaceuticals' Non-Current Assets (Quarter) stood at $75.6 million in 2021, then soared by 73.85% to $131.5 million in 2022, then soared by 63.96% to $215.6 million in 2023, then surged by 240.66% to $734.3 million in 2024, then decreased by 6.66% to $685.4 million in 2025.
  • Its last three reported values are $685.4 million in Q3 2025, $715.2 million for Q2 2025, and $721.1 million during Q1 2025.